PL2272863T3 - Pochodne poa p 5 o zredukowanej alergeniczności i zakonserwowanej reaktywności komórek t - Google Patents

Pochodne poa p 5 o zredukowanej alergeniczności i zakonserwowanej reaktywności komórek t

Info

Publication number
PL2272863T3
PL2272863T3 PL10009855T PL10009855T PL2272863T3 PL 2272863 T3 PL2272863 T3 PL 2272863T3 PL 10009855 T PL10009855 T PL 10009855T PL 10009855 T PL10009855 T PL 10009855T PL 2272863 T3 PL2272863 T3 PL 2272863T3
Authority
PL
Poland
Prior art keywords
poa
conserved
derivatives
reactivity
cell reactivity
Prior art date
Application number
PL10009855T
Other languages
English (en)
Polish (pl)
Inventor
Martin Wald
Oliver Cromwell
Andreas Nandy
Helga Kahlert
Bernhard Weber
Helmut Fiebig
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PL2272863T3 publication Critical patent/PL2272863T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/35Allergens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55561CpG containing adjuvants; Oligonucleotide containing adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL10009855T 2003-06-04 2004-05-06 Pochodne poa p 5 o zredukowanej alergeniczności i zakonserwowanej reaktywności komórek t PL2272863T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10325508 2003-06-04
EP04739147A EP1629006B1 (de) 2003-06-04 2004-05-06 Phl p 5a-derivate mit reduzierter allergenität und erhaltener t-zellreaktivität
EP10009855A EP2272863B1 (de) 2003-06-04 2004-05-06 Poa p 5-Derivate mit reduzierter Allergenität und erhaltener T-Zellrealktivität

Publications (1)

Publication Number Publication Date
PL2272863T3 true PL2272863T3 (pl) 2013-03-29

Family

ID=33494849

Family Applications (2)

Application Number Title Priority Date Filing Date
PL10009855T PL2272863T3 (pl) 2003-06-04 2004-05-06 Pochodne poa p 5 o zredukowanej alergeniczności i zakonserwowanej reaktywności komórek t
PL10009856T PL2287180T3 (pl) 2003-06-04 2004-05-06 Pochodne Lol p 5 o zredukowanej alergeniczności i utrzymanej reaktywności dla komórek T

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL10009856T PL2287180T3 (pl) 2003-06-04 2004-05-06 Pochodne Lol p 5 o zredukowanej alergeniczności i utrzymanej reaktywności dla komórek T

Country Status (13)

Country Link
US (3) US8628946B2 (enExample)
EP (3) EP2272863B1 (enExample)
JP (2) JP4782671B2 (enExample)
CN (1) CN1798763B (enExample)
AT (1) ATE513848T1 (enExample)
AU (1) AU2004245184B2 (enExample)
BR (1) BRPI0410908A (enExample)
CA (1) CA2528053C (enExample)
ES (3) ES2434720T3 (enExample)
PL (2) PL2272863T3 (enExample)
PT (3) PT2287180E (enExample)
RU (1) RU2368620C2 (enExample)
WO (1) WO2004108758A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR779201A0 (en) 2001-09-20 2001-10-11 University Of Melbourne, The Immunotherapeutic and immunoprophylactic reagents
PT2287180E (pt) * 2003-06-04 2013-10-31 Merck Patent Gmbh Derivados de lol p 5 com alergenicidade reduzida e reatividade mantida com as células t
AT503690A1 (de) * 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
US9975932B2 (en) 2010-01-14 2018-05-22 Merck Patent Gmbh Variants of group 5 allergens of the true grasses having reduced allergeneity due to mutagenesis of proline residues
KR20240055084A (ko) 2021-09-13 2024-04-26 라이프 테크놀로지스 코포레이션 유전자 편집 도구

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736362A (en) * 1990-10-26 1998-04-07 The University Of Melbourne Ryegrass pollen allergen
DE19713001A1 (de) 1997-03-27 1998-10-01 Merck Patent Gmbh Graminaenpollenallergenmutanten zur spezifischen Immuntherapie, deren Herstellung und Verwendung
DE19918682A1 (de) 1999-04-23 2000-10-26 Merck Patent Gmbh DNA-Sequenz und rekombinante Herstellung eines Graminaen-Allergens
IT1318692B1 (it) 2000-09-12 2003-08-27 Consiglio Nazionale Ricerche Varianti di proteine allergeniche di phleum pratense.
DE60136653D1 (de) * 2000-11-16 2009-01-02 Alk Abello As Mutante allergene
AUPR779201A0 (en) * 2001-09-20 2001-10-11 University Of Melbourne, The Immunotherapeutic and immunoprophylactic reagents
PT2287180E (pt) * 2003-06-04 2013-10-31 Merck Patent Gmbh Derivados de lol p 5 com alergenicidade reduzida e reatividade mantida com as células t

Also Published As

Publication number Publication date
CA2528053C (en) 2014-08-12
JP2007536893A (ja) 2007-12-20
ES2434720T3 (es) 2013-12-17
PL2287180T3 (pl) 2013-12-31
JP4782671B2 (ja) 2011-09-28
EP2272863A1 (de) 2011-01-12
CA2528053A1 (en) 2004-12-16
ES2397778T3 (es) 2013-03-11
PT2272863E (pt) 2013-01-30
AU2004245184A1 (en) 2004-12-16
WO2004108758A1 (de) 2004-12-16
AU2004245184B2 (en) 2011-03-24
EP2287180A1 (de) 2011-02-23
US20160207967A1 (en) 2016-07-21
US8628946B2 (en) 2014-01-14
US20140255434A1 (en) 2014-09-11
ES2367633T3 (es) 2011-11-07
RU2005141524A (ru) 2006-09-10
JP2011041566A (ja) 2011-03-03
PT1629006E (pt) 2011-09-28
EP2287180B9 (de) 2013-11-06
EP1629006B1 (de) 2011-06-22
BRPI0410908A (pt) 2006-06-27
EP1629006A1 (de) 2006-03-01
JP5363441B2 (ja) 2013-12-11
CN1798763B (zh) 2010-05-26
US20100158955A1 (en) 2010-06-24
PT2287180E (pt) 2013-10-31
EP2287180B1 (de) 2013-08-07
RU2368620C2 (ru) 2009-09-27
ATE513848T1 (de) 2011-07-15
US9522938B2 (en) 2016-12-20
EP2272863B1 (de) 2012-10-31
CN1798763A (zh) 2006-07-05

Similar Documents

Publication Publication Date Title
US20230065226A1 (en) Homodimeric protein constructs
JP2023515386A (ja) 制御性t細胞エピトープと脱寛容化sars-cov-2抗原
Cao et al. Toxoplasma gondii: vaccination with a DNA vaccine encoding T-and B-cell epitopes of SAG1, GRA2, GRA7 and ROP16 elicits protection against acute toxoplasmosis in mice
WO2009154995A3 (en) Interleukin 10 receptor (il-10r) antibodies and methods of use
WO2003049762A3 (en) Immunisation against chlamydia trachomatis
CA2555342A1 (en) Polypeptides for inducing a protective immune response against staphylococcus aureus
IN2009CN03372A (enExample)
MY149128A (en) A method for the mass production of immunoglobulin fc region deleted initial methionine residues
CN113015541A (zh) 具有新氧化还原酶基序的免疫原性肽
PL2272863T3 (pl) Pochodne poa p 5 o zredukowanej alergeniczności i zakonserwowanej reaktywności komórek t
EP1219301B1 (en) Vaccines containing hybrid polypeptides consisting of at least two different allergenic proteins
WO2009129521A3 (en) Immunodominant mycobacterium tuberculosis peptides from cell wall proteins for early diagnosis and immunization
WO2004018515A3 (en) T-cell epitopes in erythropoietin
PT1768996E (pt) Variantes dos alergénios do grupo 1 das poaceae com alergenecidade reduzida e mantendo a reactividade das células t
TW200716166A (en) Lawsonia intracellularis immunological proteins
WO2003093416A3 (en) Protective antigens for the control of ixodes species infestations
PL400683A1 (pl) Sekwencja DNA oraz sposób otrzymywania rekombinowanego alergenu pylku traw PHL P4
WO2013011184A3 (es) Molécula quimerica util en inmunoterapia frente a la leishmaniosis, que comprende un fragmento de la proteina pfr1 de leishmania infantum con epitopes especificos inmunodominantes
PL363501A1 (en) Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity
NZ593086A (en) Isolated peptide binding to human leukocyte antigen (HLA) and having cytotoxic T lymphocyte (CTL) inducibility
SG156619A1 (en) Novel cancer associated antibodies and antigens and their use in cancer diagnosis
WO2004113361A3 (en) Novel prokineticin receptor isoforms and methods of use
Ågren et al. A genetically engineered non-toxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit
WO2007042326A3 (en) Neisseria meningitidis antigens
WO2006058277A3 (en) Method for identifying and designing immunogenic peptides